PAHC vs. MRUS, CRSP, TGTX, CYTK, AAPG, KRYS, ACAD, ADMA, TLX, and PCVX
Should you be buying Phibro Animal Health stock or one of its competitors? The main competitors of Phibro Animal Health include Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), Ascentage Pharma Group International (AAPG), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), Telix Pharmaceuticals (TLX), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.
Phibro Animal Health vs. Its Competitors
Phibro Animal Health (NASDAQ:PAHC) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.
Phibro Animal Health currently has a consensus target price of $28.40, suggesting a potential downside of 27.31%. Merus has a consensus target price of $88.75, suggesting a potential upside of 34.00%. Given Merus' stronger consensus rating and higher probable upside, analysts clearly believe Merus is more favorable than Phibro Animal Health.
99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 3.7% of Merus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Phibro Animal Health has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
In the previous week, Phibro Animal Health had 1 more articles in the media than Merus. MarketBeat recorded 15 mentions for Phibro Animal Health and 14 mentions for Merus. Merus' average media sentiment score of 1.45 beat Phibro Animal Health's score of 0.63 indicating that Merus is being referred to more favorably in the news media.
Phibro Animal Health has a net margin of 3.73% compared to Merus' net margin of -685.64%. Phibro Animal Health's return on equity of 32.14% beat Merus' return on equity.
Phibro Animal Health has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Summary
Phibro Animal Health beats Merus on 10 of the 17 factors compared between the two stocks.
Get Phibro Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAHC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phibro Animal Health Competitors List
Related Companies and Tools
This page (NASDAQ:PAHC) was last updated on 9/5/2025 by MarketBeat.com Staff
